文献速递免疫规划传染病防控与疫情报告

2021年Alpha和Delta变异株流行期间成人(≥20岁)COVID-19住院疫苗有效性:I-MOVE-COVID-19与VEBIS SARI VE网络

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
PubMed 文献 · Euro Surveill · 2023-01-01

Alpha期完整基础免疫针对Comirnaty住院VE为85%,Delta期升至加强针后91%。

要点

  • Alpha期完整Comirnaty基础免疫住院VE为85%(95%CI:69-92)
  • Delta期完成基础免疫≥150天者VE降至54%(95%CI:18-74)
  • 基础免疫后加mRNA加强针≥150天者VE升至91%(95%CI:57-98)

核心结论

  • 在欧盟多国医院环境中,完整基础免疫的VE在Alpha优势期高于Delta优势期,Delta期加首剂加强针后VE升至90%以上。

研究设计与样本

  • Alpha优势期(2021年3-6月)纳入1087例病例(538例对照),Delta优势期(2021年6-12月)纳入1669例病例(1442例对照)。
  • 完整基础免疫定义为两剂次疫苗的2剂或单剂次疫苗的1剂,且在发病前≥14天完成。

主要发现

  • Alpha期完整Comirnaty基础免疫总体住院VE为85%(95%CI:69-92),≥80岁人群为75%(95%CI:42-90)。
  • Delta期症状发作距末次基础免疫剂量≥150天的SARI患者中,完整Comirnaty基础免疫VE为54%(95%CI:18-74)。
  • Delta期接受Comirnaty基础免疫且末次剂量后≥150天接种mRNA加强针(任何产品)者VE为91%(95%CI:57-98)。
  • 接种时间分析显示,完整全产品基础免疫在末次剂量后<90天VE>90%,90-179天VE≥70%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Rose AM, Nicolay N, Sandonis Martín V, et al. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021. Euro Surveill. 2023. PMID: 37997666. doi:10.2807/1560-7917.ES.2023.28.47.2300186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。